This article was originally published in Start Up
Two-dimensional gel techniques have improved over the years, but remain insufficient to address the complex questions confronting today's proteomics researchers. Proteome Inc. is working on longer gel formats which will enable it to detect the entire proteome of organisms like yeast on a single gel.
You may also be interested in...
Advocates of proteomics argue that without an understanding of protein interactions, drug researchers will be attempting to paint Old Masters with an incomplete set of genomic paint-by-number instructions.
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.